Group 1 - The core viewpoint of the news is that Yinosh Biotechnology Co., Ltd. has seen a stock price increase of 5.11%, reaching 50.80 CNY per share, with a total market capitalization of 7.162 billion CNY as of September 25 [1] - Yinosh specializes in providing non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services, 3.42% from clinical services, and 0.27% from other sources [1] - The company is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010, with its listing date set for September 3, 2024 [1] Group 2 - Among Yinosh's top ten circulating shareholders, a fund under Harvest Fund Management, specifically the Harvest Medical Health Stock A (005303), has entered the top ten, holding 344,300 shares, which is 1.22% of the circulating shares [2] - The Harvest Medical Health Stock A fund has achieved a year-to-date return of 46.46%, ranking 892 out of 4220 in its category, and a one-year return of 60.55%, ranking 1402 out of 3820 [2] - The fund was established on December 4, 2017, and has a current size of 786 million CNY, with an overall return since inception of 99.56% [2] Group 3 - The fund manager of Harvest Medical Health Stock A is Sun Xiaohui, who has been in the position for 168 days, achieving a best return of 39.35% during his tenure [3] - The other fund manager, Hao Miao, has been managing the fund for 6 years and 254 days, with a best return of 183.83% and a worst return of -29.32% during his tenure [3]
益诺思股价涨5.11%，嘉实基金旗下1只基金位居十大流通股东，持有34.43万股浮盈赚取85.05万元